PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 1 year 3 months ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
BRIEF published on 03/27/2025 at 07:35, 1 year 4 months ago MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results Financial Results Biotechnology Capital Increase MaaT013 AGvH
BRIEF published on 01/21/2025 at 18:05, 1 year 6 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 7 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 1 year 9 months ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 9 months ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
BRIEF published on 09/04/2024 at 07:35, 1 year 11 months ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
BRIEF published on 05/15/2024 at 07:35, 2 years 2 months ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
PRESS RELEASE published on 05/15/2024 at 07:30, 2 years 2 months ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
Published on 08/04/2026 at 22:30, 1 hour 33 minutes ago Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 16:25, 7 hours 38 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 9 hours 3 minutes ago Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Published on 08/04/2026 at 15:00, 9 hours 3 minutes ago Secure Blockchain's Agentic Solutions Signs First Enterprise AI Customer
Published on 08/04/2026 at 22:03, 1 hour 59 minutes ago #FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised
Published on 08/04/2026 at 22:01, 2 hours 2 minutes ago EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
Published on 08/04/2026 at 20:05, 3 hours 58 minutes ago Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:39, 4 hours 23 minutes ago EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Published on 08/04/2026 at 18:32, 5 hours 30 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 6 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/04/2026 at 16:00, 8 hours 3 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 08/04/2026 at 08:15, 15 hours 48 minutes ago Covivio - Conditions of availability of the 2026 Half-year report
